Dr. Chiang Syin appointed Chief Quality Officer of Wuxi Biologics

Gobal open-access biologics technology platform company, Wuxi Biologics declares that Dr. Chiang Syin has been appointed by Wuxi Biologics as its Chief Quality Officer accountable for assuring quality , quality control laboratories and regulatory affairs.

Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, “Dr. Syin’s nearly 30 years of experience at US FDA and CFDA (China Food and Drug Administration) biologics quality and compliance will accelerate our path to build a world-class quality organization for biologics commercial manufacturing.”

Dr. Chiang Syin brings with nearly 30 years of expertise and eperience in FDA regulatory assessment and GMP compliance of biological and biotech products. Prior to joining Wuxi Biologics, he was a GATES Project international expert for the Center for Food and Drug Inspection of CFDA (CFDI). From 2012 to February 2017, having  served as a Branch Chief in the Office of Compliance and Biologics Quality, the Center for Biologics Evaluation and Research (CBER). He was accountable for assisting staff in  Chemistry, Manufacturing and Control reviews and GMP inspections for premarketing license applications and post marketing changes of the biological products.

Postdoctoral training in NIAID institute of Allergy and Infectious Diseases, NIH and performed regulatory reviews of IND and BLA in addition to malaria research.